Our Malaysia facility is focussed on insulin & insulin analogues: Kiran Mazumdar Shaw, Biocon
It is likely to take some time before we can actually start very aggressively marketing globally from the Malaysia facility.
In an interview with ET Now, Kiran Mazumdar Shaw, CMD, Biocon, shares her business outlook. Excerpts:
ET Now: Let us start by understanding what is happening with biosimilar business that has shown some traction after a few quarters of sluggish growth. What led to this growth in this particular segment this time around?